John Jefferies
Advanced Heart Failure and Transplant Cardiology · Memphis, TNNPI 1619920469
Payments from drug & device makers
Across 627 payments — averaging $2305.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$522K
- Nuwellis, Inc.$360K
- Sanofi$138K
- E.r. Squibb & Sons, L.L.C.$119K
- Abbott$59K
- Novartis$56K
- plus $192K from 31 others
Across 15 payments — averaging $459.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
- Sanofi$2K
- Eli Lilly$1K
- Medtronic$693
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 27 | $522,078 |
| Nuwellis, Inc. | 75 | $359,973 |
| Sanofi | 91 | $137,784 |
| E.r. Squibb & Sons, L.L.C. | 54 | $119,081 |
| Abbott | 69 | $59,296 |
| Novartis | 7 | $55,697 |
| Amicus Therapeutics, Inc. | 38 | $39,054 |
| Medtronic(3 entities) | 99 | $34,573 |
| NS Pharma, Inc. | 45 | $31,610 |
| Daxor Corporation | 29 | $18,103 |
| Pfizer | 15 | $16,136 |
| Chiesi USA, Inc. | 9 | $13,706 |
| Endologix LLC | 6 | $6,526 |
| Cvrx, Inc. | 14 | $5,869 |
| Alnylam Pharmaceuticals Inc. | 5 | $5,590 |
| Veru Inc. | 2 | $5,450 |
| Myocardial Solutions, Inc. | 2 | $5,028 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,502 |
| Eli Lilly | 1 | $2,500 |
| AstraZeneca | 3 | $1,117 |
| Bioverativ Therapeutics Inc. | 1 | $613 |
| Orpyx Medical Technologies Inc. | 1 | $400 |
| Elucent Medical | 11 | $328 |
| Bristol Myers Squibb | 1 | $300 |
| Johnson & Johnson | 4 | $248 |
| Bayer | 3 | $217 |
| Janssen Scientific Affairs, LLC | 2 | $171 |
| Bardy Diagnostics, Inc. | 1 | $125 |
| Akcea Therapeutics, Inc. | 2 | $112 |
| Vivaquant Inc, Dba Rhythm Express | 2 | $64 |
| Novo Nordisk | 1 | $38 |
| Sanofi-aventis U.S. LLC | 1 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Amgen | 1 | $17 |
| Boston Scientific | 1 | $16 |
How this compares
$1,445,422 in reported general payments places this provider in the 95th percentile of 28 advanced heart failure and transplant cardiology providers in Tennessee.
See all advanced heart failure and transplant cardiology providers in Tennessee →
Other advanced heart failure and transplant cardiology in Memphis
- Dmitry YaranovMemphis$1.1M
- Jeffrey TowbinMemphis$312K
- Kaitlin RyanMemphis$31K
- Elyse MillerMemphis$2K
- Osama MahmoudMemphis$1K
- Nobuyuki IkedaMemphis$373
- Lynne StevensonNashville$720K
- Mark AaronNashville$146K
- Jonathan MenachemNashville$79K
- Richa GuptaNashville$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.